Results 71 to 80 of about 13,147 (207)
Improving Advance Care Planning for People with Parkinson's
Movement Disorders Clinical Practice, EarlyView.
Bradley Lonergan +4 more
wiley +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 7, July 2026.LncA2M‐AS1 targets CFL1 mRNA and destabilizes ROCK1 via ubiquitination. LncA2M‐AS1 in OM‐MSC exosomes targets CFL1 mRNA, modulating the CFL1–ROCK1 pathway to reprogram microglial glucose metabolism, suppress neuroinflammation, and ultimately protect dopaminergic neurons and reduce neuroinflammation in PD mice.
Jiangshan Zhang +6 more
wiley +1 more source
Apomorphine Penject – Emerging Evidence and Treatment Strategies for Delayed on and off Periods in Parkinson’s disease [PDF]
, 2014 This educational symposium was held during the Joint Congress of European Neurology (EFNS–ENS), which took place from 31st May to 3rd June 2014 in Istanbul, Turkey, and was sponsored by Britannia Pharmaceuticals Limited. The symposium debated the problem
William Ondo +3 more
core
Food Frontiers, Volume 7, Issue 4, July 2026.The schematic diagram illustrating the improvement mechanisms of six typical FMH substances and their main active ingredients in different sleep disorders. ABSTRACT Sleep integrates many brain and peripheral processes, profoundly influencing well‐being.
Wenjing Wen +9 more
wiley +1 more source
Apomorphine is a potent inhibitor of ferroptosis independent of dopaminergic receptors
Scientific ReportsOriginally, apomorphine was a broad-spectrum dopamine agonist with an affinity for all subtypes of the Dopamine D1 receptor to the D5 receptor. We previously identified apomorphine as a potential therapeutic agent for mitochondrial diseases by screening ...
Akihiko Miyauchi +13 more
doaj +1 more source
Macromolecular Rapid Communications, Volume 47, Issue 14, 20 July 2026.Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley +1 more source
Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats [PDF]
, 2010 Adolescence is a critical period for neurodevelopment Disturbances during adolescence have significant deleterious effects on brain function and animal behavior Latent inhibition refers to the process in which pre exposure to a stimulus retards ...
Wang, Weiwen +4 more
core
Low–dose apomorphine challenge in tardive akathisia [PDF]
, 1993 We challenged seven tardive akathisia patients with low-dose apomorphine (0.01 mg/kg) SC and placebo in a double-blind, random design. Apomorphine caused a significantly greater reduction in the objective (movement) but not the subjective (distress ...
Loneragan, C +1 more
core +2 more sources
Movement Disorders Clinical Practice, Volume 13, Issue 7, Page 1730-1739, July 2026.Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner +10 more
wiley +1 more source
Movement Disorders Clinical Practice, Volume 13, Issue 7, Page 1662-1672, July 2026.Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig +6 more
wiley +1 more source